Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum.

ABSTRACT:

Background

Genogroup II noroviruses are the most common cause of acute infectious gastroenteritis. We evaluated the use of a new GII.2 inoculum in a human challenge.

Methods

Forty-four healthy adults (36 secretor-positive and 8 secretor-negative for histo-blood group antigens) were challenged with ascending doses of a new safety-tested Snow Mountain virus (SMV) GII.2 norovirus inoculum (1.2 × 104 to 1.2 × 107 genome equivalent copies [GEC]; n = 38) or placebo (n = 6). Illness was defined as diarrhea and/or vomiting postchallenge in subjects with evidence of infection (defined as GII.2 norovirus RNA detection in stool and/or anti-SMV immunoglobulin G [IgG] seroconversion).

Results

The highest dose was associated with SMV infection in 90%, and illness in 70% of subjects

SUBMITTER: Rouphael N 

PROVIDER: S-EPMC9650503 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature